GlassScriptPhysician profile
Vijay Reddy
NPI 1164480802
$2,103.40
in general payments reported to CMS, 2019-2025
18 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.67 · 2020: $170 · 2021: $128 · 2022: $299 · 2023: $676 · 2024: $368 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.12 |
| Education | $137.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $989.27 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $310.49 | 2020-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $203.81 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $95.46 | 2022-2025 | Breztri, Fasenra, Andexxa |
| Merck Sharp & Dohme LLC | $79.01 | 2019-2024 | Winrevair |
| Mylan Specialty L.P. | $76.10 | 2022-2023 | Yupelri |
| Vifor Pharma, INC. | $74.53 | 2024-2025 | Veltassa |
| Genzyme Corporation | $47.31 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.97 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.73 | 2022 | |
| Grifols USA, LLC | $26.74 | 2023 | Prolastin-C Liquid |
| Janssen Biotech, INC. | $25.05 | 2025 | Tremfya |
| Medtronic, INC. | $23.34 | 2022 | |
| Fisher & Paykel Healthcare INC | $23.03 | 2024 | Fisher & Paykel Healthcare |
| Amgen INC. | $18.38 | 2023 | Tezspire |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $17.63 | 2023 | Tyvaso |
| La Jolla Pharmaceutical Company | $16.48 | 2022 | |
| Ambu INC. | $15.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.